Vergnenègre, A <br/><br/>
Cost analysis of hospital treatment--two chemotherapic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Français Pneumo Cancérologie)  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  Feb 1996 
 - 31-44 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0169-5002 
<br/><br/><label>Standard No.: </label>10.1016/0169-5002(95)00511-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibiotics, Antineoplastic--economics<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--economics<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Cisplatin--economics<br/>Cost-Benefit Analysis<br/>Direct Service Costs--statistics & numerical data<br/>Drug Costs--statistics & numerical data<br/>Female<br/>France<br/>Health Services Research--methods<br/>Hospital Costs--statistics & numerical data<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mitomycins--economics<br/>Models, Economic<br/>Oncology Service, Hospital--economics<br/>Prospective Studies<br/>Quality-Adjusted Life Years<br/>Retrospective Studies<br/>Sensitivity and Specificity<br/>Treatment Outcome<br/>Vinblastine--analogs & derivatives<br/>Vindesine--economics<br/>Vinorelbine